A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 257-264

  Hashiguchi, Kazuyoshi ^a   Kitajima, Yoshihiko ^a   Kai, Keita ^a   Hiraki, Masatsugu ^a   Nakamura, Jun ^a   Tokunaga, Osamu ^a   Noshiro, Hirokazu ^a   Miyazaki, Kohji ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Gastric cancer; qDFIHC; S 1; Tailor made chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT; OXONIC ACID; PHARMACOLOGICAL BIOMARKER; S 1 (COMBINATION); TEGAFUR; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MALE; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STOMACH BIOPSY; STOMACH CANCER; TREATMENT OUTCOME; ADJUVANT THERAPY; BIOPSY; CARCINOMA; DISEASE COURSE; DRUG COMBINATION; EVALUATION; LABORATORY DIAGNOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; STOMACH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; BIOPSY; CARCINOMA; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OXONIC ACID; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SPECIMEN HANDLING; STOMACH NEOPLASMS; TEGAFUR; TUMOR MARKERS, BIOLOGICAL;

EID: 77954166214     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000673     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996. (Pubitemid 26276346)
3. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993. (Pubitemid 23267702)
4. Boku N: Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol 13: 483-487, 2008.
5. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (spirits trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
6. Kinoshita T, Sasako M, Sano T, et al: Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer 12: 37-42, 2009.
7. Hartgrink HH: Improving outcome for scirrhous gastric cancer. Gastric Cancer 12: 3-5, 2009.
8. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
9. Ichikawa W, Takahashi T, Suto K, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 112: 967-973, 2004. (Pubitemid 39507002)
10. Ichikawa W, Takahashi T, Suto K, et al: Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 119: 1927-1933, 2006.
11. Ichikawa W, Takahashi T, Suto K, et al: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91: 1245-1250, 2004. (Pubitemid 39424782)
12. Ichikawa W, Uetake H, Shirota Y, et al: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791, 2003.
13. Kai K, Kitajima Y, Hiraki M, et al: Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens. Cancer Lett 258: 45-54, 2007.
14. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
15. Matsuyama R, Togo S, Shimizu D, et al: Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three-gene expression model predicts clinical response. Int J Cancer 119: 406-413, 2006.
16. Miyazaki K, Shibahara T, Sato D, et al: Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol 41: 140-150, 2006.
17. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
18. Sato K, Kitajima Y, Miyoshi A, Koga Y and Miyazaki K: Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. Int J Oncol 29: 429-435, 2006.
19. Sakurai Y, Sakamoto K, Sugimoto Y, et al: Orotate phosphoribosyltransferase levels measured by a newly established enzyme-linked immunosorbent assay in gastric carcinoma. Cancer Sci 97: 492-498, 2006.
20. Tsuchida M, Yamato Y, Hashimoto T, et al: Expression of 5-fluorouracil-related enzymes in lung cancer: ELISA characterizes enzyme activity and messenger RNA expression. Oncol Rep 21: 1037-1043, 2009.
21. Sobin LH: TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 21: 19-22, 2003.
22. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 m tegafur-0.4 m gimestat-1 m otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
23. Japanese classification of gastric carcinoma - 2nd English edition-response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 4: 1-8, 2001.
24. Muller G: [General guidelines for surgery and pathology of the Japanese Research Society for Gastric Cancer]. Chirurg 56: 539-552, 1985.
25. D'Ugo D, Rausei S, Biondi A and Persiani R: Preoperative treatment and surgery in gastric cancer: friends or foes? Lancet Oncol 10: 191-195, 2009.
26. Mercer SJ, Somers SS, Knight LA, et al: Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anticancer Drugs 14: 397-403, 2003. (Pubitemid 36951788)
27. Schlag P and Schreml W: Heterogeneity in growth pattern and drug sensitivity of primary tumor and metastases in the human tumor colony-forming assay. Cancer Res 42: 4086-4089, 1982. (Pubitemid 13198569)